The amendment is a non-cash strategic alignment with no near-term revenue catalyst. Monitor for 2027 regulatory decisions in China and any subsequent milestone triggers. The equity stake provides optional upside but is highly speculative given Nicoya's private status and long timeline.
Price Chart
Executive Summary
OPKO Health announced an amendment to its Nicoya Therapeutics agreement, receiving a 15% equity stake in Nicoya in exchange for revised royalty/transfer pricing, while keeping the $115M milestone structure intact. The deal deepens strategic alignment for RAYALDEE commercialization in Greater China, where regulatory approvals are expected in 2027, but provides no immediate revenue or cash consideration.
Key Facts
- OPKO received a 15% equity stake in Nicoya via Series A-2 Preferred Shares in two tranches.
- Revised tiered royalty and transfer price schedule replaces prior terms; milestone payments up to $115M unchanged.
- RAYALDEE approved in Macau; regulatory approvals in China and related territories expected in 2027.
- No upfront cash payment or immediate revenue recognized from the amendment.
- OPKO's market cap is ~$843M; the equity stake value and milestone potential are unquantified in the release.
Financial Impact
Equity stake of 15% in Nicoya (private, unvalued); milestone potential up to $115M but contingent on future regulatory/sales events; no immediate cash flow impact.
Risk Factors
- Regulatory approvals in China may be delayed or denied, impairing milestone and royalty potential.
- Equity stake in private Nicoya is illiquid and may never generate realized value.
- RAYALDEE faces competition from existing vitamin D therapies and SHPT treatments in China.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3284852 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 27, 2026 9w ago | 8-K | $1.65 $1.49 | ▼ −9.70% | ▼ −13.08% | $1.56 (−5.45%) |
Jul 23, 2026 10w ago | Press Release | $1.17 $1.46 | ▲ +24.79% | ▲ +21.48% | $1.56 (+33.33%) |
Jun 15, 2026 15w ago | Press Release | $1.40 $1.23 | ▼ −12.14% | ▼ −11.39% | $1.56 (+11.43%) |
May 15, 2026 20w ago | DEFA14A | $1.13 $1.39 | ▲ +23.01% | ▲ +21.43% | $1.56 (+38.05%) |
Apr 30, 2026 22w ago | Press Release | $1.13 $1.43 | ▲ +26.55% | ▲ +21.58% | $1.56 (+38.05%) |
Apr 22, 2026 23w ago | Press Release | $1.23 $1.15 | ▼ −6.50% | ▼ −9.67% | $1.56 (+26.83%) |
Apr 21, 2026 23w ago | Press Release | $1.23 $1.15 | ▼ −6.50% | ▼ −9.67% | $1.56 (+26.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access